Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Oculis Holding AG

Oculis to Participate in Upcoming September Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis Reports Q2 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis Upsized Loan Facility to Access up to CHF 100 million
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis Publishes Results of 2025 Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis to Participate in Upcoming June Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis Publishes Invitation to the Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis Reports Q1 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis to Present at Upcoming May Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
From Oculis Holding AG
Via GlobeNewswire
Tickers OCS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.